Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) trial. While mRNA-1273 demonstrated high eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Pajon, Rolando, Paila, Yamuna D., Girard, Bethany, Dixon, Groves, Kacena, Katherine, Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Mullane, Kathleen M., Frank, Ian, Denhan, Douglas, Kerwin, Edward, Zhao, Xiaoping, Ding, Baoyu, Deng, Weiping, Tomassini, Joanne E., Zhou, Honghong, Leav, Brett, Schödel, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018421/
https://www.ncbi.nlm.nih.gov/pubmed/35145311
http://dx.doi.org/10.1038/s41591-022-01679-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018421/
https://www.ncbi.nlm.nih.gov/pubmed/35145311
http://dx.doi.org/10.1038/s41591-022-01679-5

Ejemplares similares